Multimodal Treatment for Mesothelioma Shows Survival Benefit

This study confirmed, by comparison, the effectiveness of multimodal treatment,” Hassan said. “But you can’t rely [on] what you see in papers. Before choosing, patients have to talk with the oncologist, the surgeon, the pulmonologist, about benefits and risks of treatment.” Benefits of Nintedanib Discussed A second research group at ELCC presented on the benefits of the drug nintedanib in combination with chemotherapy for patients with mesothelioma. The report was part of a phase III clinical trial. Nintedanib, which is marketed as Ofev or Vargatef, is a small-molecule enzyme inhibitor which has shown an ability to slow tumor spread and prevent mesothelioma growth. According to the presentation, it worked best on patients with lower levels of endoglin, a specific protein found on cell surfaces that encourages tumor growth. “The progression-free and overall survival benefit of nintedanib appeared more pronounced in patients with baseline endoglin levels below the median,” said lead author Dr. Nick Pavlakis, Northern Cancer Institute in New South Wales, Australia. Nintedanib, which is available in the U.S. only through clinical trials, was granted early-access designation for mesothelioma by the United Kingdom regulatory agency earlier this year. The post Multimodal Treatment for Mesothelioma Shows Survival Benefit appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news